Overview
Section titled “Overview”Semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1/GIP receptor agonist) represent the two leading incretin-based therapies for obesity and type 2 diabetes. This comparison integrates the latest 2025 clinical data, including completed phase 3 trials, new FDA indications, and head-to-head results.
Mechanism of Action
Section titled “Mechanism of Action”Semaglutide
Section titled “Semaglutide”Semaglutide is a selective GLP-1 receptor agonist with ~94% homology to native human GLP-1. It activates the GLP-1R on pancreatic beta cells, hypothalamic neurons, and gastrointestinal tissue. Key pharmacological effects include glucose-dependent insulin secretion, delayed gastric emptying, reduced appetite via central satiety signaling, and cardioprotective effects through endothelial function improvement.
Tirzepatide
Section titled “Tirzepatide”Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is a linear 39-amino-acid peptide with a C-20 fatty diacid moiety enabling albumin binding. Tirzepatide activates both GIPR and GLP-1R, with slightly higher affinity for GIPR (Kd = 0.14 nM) than GLP-1R (Kd = 0.18 nM). The dual mechanism produces additive or synergistic effects on insulin secretion, appetite suppression, and energy expenditure.
Efficacy: Weight Loss
Section titled “Efficacy: Weight Loss”STEP Program (Semaglutide)
Section titled “STEP Program (Semaglutide)”The STEP (Semaglutide Treatment Effect in People with obesity) program established semaglutide 2.4 mg weekly as a first-in-class anti-obesity medication:
| Trial | Population | Duration | Mean Weight Loss |
|---|---|---|---|
| STEP 1 | Non-diabetic obesity | 68 weeks | −14.9% |
| STEP 2 | T2D with obesity | 68 weeks | −9.6% |
| STEP 3 | Intensive behavioral therapy | 68 weeks | −16.0% |
| STEP 4 | Withdrawal study | 68 weeks | −17.4% (maintained) |
| SELECT | CV outcomes | 39 months | −9.4% (HR 0.80 for MACE) |
SURMOUNT Program (Tirzepatide)
Section titled “SURMOUNT Program (Tirzepatide)”The SURMOUNT program evaluated tirzepatide (5 mg, 10 mg, 15 mg) for chronic weight management:
| Trial | Population | Duration | Mean Weight Loss (15 mg) |
|---|---|---|---|
| SURMOUNT-1 | Non-diabetic obesity | 72 weeks | −20.9% |
| SURMOUNT-2 | T2D with obesity | 72 weeks | −12.8% |
| SURMOUNT-3 | Intensive lifestyle | 72 weeks | −24.3% |
| SURMOUNT-4 | Maintenance | 72 weeks | −25.4% (ongoing) |
Head-to-Head: SURPASS-2
Section titled “Head-to-Head: SURPASS-2”The SURPASS-2 trial directly compared tirzepatide (5, 10, 15 mg) with semaglutide 1 mg in patients with T2D:
- Tirzepatide 5 mg: −1.8 kg additional weight loss vs semaglutide
- Tirzepatide 10 mg: −3.7 kg additional weight loss
- Tirzepatide 15 mg: −5.5 kg additional weight loss
Note: SURPASS-2 used semaglutide 1 mg (diabetes dose), not the 2.4 mg obesity dose. Direct comparison with semaglutide 2.4 mg is pending in dedicated trials.
Cardiovascular Outcomes
Section titled “Cardiovascular Outcomes”Semaglutide (SELECT Trial)
Section titled “Semaglutide (SELECT Trial)”The SELECT trial (n=17,604) demonstrated:
- 20% reduction in MACE (HR 0.80, 95% CI 0.72–0.90)
- 18% reduction in cardiovascular death
- 15% reduction in heart failure events
- NNT = 67 over 39 months for primary endpoint
Tirzepatide (SURPASS-CVOT)
Section titled “Tirzepatide (SURPASS-CVOT)”The SURPASS-CVOT trial completed enrollment in 2024 with results expected in 2025:
- Primary endpoint: MACE (3-point) vs semaglutide 1 mg
- Enrollment: ~13,000 patients with T2D and established CVD
- Results pending as of Q1 2025
New Indications (2024–2025)
Section titled “New Indications (2024–2025)”Semaglutide
Section titled “Semaglutide”- Obesity (BMI ≥30 or ≥27 with comorbidity): FDA approved (Wegovy)
- Cardiovascular risk reduction: FDA approved 2024 (SELECT label expansion)
- Heart failure with preserved ejection fraction: Phase 3 completed; FDA filing expected 2025
- Chronic kidney disease: FLOW trial stopped early for efficacy; FDA filing 2025
- MASH (metabolic-associated steatohepatitis): Phase 3 in progress
Tirzepatide
Section titled “Tirzepatide”- Obesity: FDA approved (Zepbound) November 2023
- Obstructive sleep apnea: FDA approved 2024 (SURMOUNT-OSA)
- Heart failure with preserved ejection fraction: Phase 3 (SURPASS-HFpEF) in progress
- MASH: Phase 2 completed; phase 3 initiated 2024
- T2D (initial monotherapy): Approved as first-line injectable
Safety Profile
Section titled “Safety Profile”Common Adverse Events
Section titled “Common Adverse Events”| Adverse Event | Semaglutide 2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| Nausea | 44% | 25% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 13% |
| Constipation | 24% | 18% |
| Injection site reaction | 8% | 5% |
| Decreased appetite | 11% | 12% |
Serious Considerations
Section titled “Serious Considerations”- Pancreatitis: Rare (0.2–0.3%), similar between agents
- Gallbladder events: Increased risk with rapid weight loss; slightly higher with semaglutide
- Medullary thyroid carcinoma: Contraindicated in MEN2 syndrome; boxed warning
- Gastroparesis: Both agents delay gastric emptying; more pronounced with semaglutide
Tirzepatide-Specific Considerations
Section titled “Tirzepatide-Specific Considerations”- Slightly lower GI tolerability burden than semaglutide at equivalent weight loss
- Potential advantage in patients with significant nausea sensitivity
- Dual mechanism may provide additional metabolic benefits (lipid profile, insulin sensitivity)
Dosing and Administration
Section titled “Dosing and Administration”Semaglutide (Wegovy)
Section titled “Semaglutide (Wegovy)”- 0.25 mg weekly × 4 weeks → 0.5 mg × 4 → 1.0 mg × 4 → 1.7 mg × 4 → 2.4 mg (maintenance)
- Subcutaneous injection, abdomen, thigh, or upper arm
- Administer same day each week, any time of day
- No relation to meals
Tirzepatide (Zepbound)
Section titled “Tirzepatide (Zepbound)”- 2.5 mg weekly × 4 weeks → 5 mg × 4 → 7.5 mg (if needed) → 10 mg → 12.5 mg → 15 mg (maintenance)
- Subcutaneous injection, abdomen, thigh, or upper arm
- Administer same day each week, any time of day
- No relation to meals
Cost and Access
Section titled “Cost and Access”| Parameter | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| List price | ~$1,350/month | ~$1,050/month |
| Insurance coverage | Variable | Variable |
| Savings card | Available | Available |
| Biosimilar status | No biosimilar yet | No biosimilar yet |
Key Differentiators Summary
Section titled “Key Differentiators Summary”| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor target | GLP-1R | GLP-1R + GIPR |
| Max weight loss (phase 3) | −16% | −25% |
| CV outcomes data | SELECT (completed) | SURPASS-CVOT (pending) |
| GI tolerability | Moderate | Better |
| Oral formulation | Rybelsus (3–14 mg, T2D only) | Oral in development |
| Approved indications | Obesity, T2D, CV risk, OSA | Obesity, T2D, OSA |
| Heart failure data | FLOW (positive) | Pending |
Conclusion
Section titled “Conclusion”Tirzepatide demonstrates superior weight loss efficacy compared to semaglutide based on available data, likely attributable to the dual GLP-1/GIP mechanism. However, semaglutide has a more established cardiovascular outcomes dataset (SELECT trial). Both agents represent major advances in obesity pharmacotherapy. The choice between them should consider patient-specific factors including weight loss goals, GI tolerability, cardiovascular risk profile, and insurance coverage.
Deep dive: Read about Clinical Trial Design for trial methodology, or explore Peptide Pharmacology for receptor-level mechanisms.
Test yourself: Take the Incretin Pharmacology Quiz or study with GLP-1 Receptor Flashcards.